NantHealth Inc (NYSE:NH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
Several other brokerages have also weighed in on NH. Jefferies Group LLC restated a “buy” rating and issued a $5.00 price objective on shares of NantHealth in a report on Thursday, September 28th. Canaccord Genuity restated a “buy” rating and issued a $6.00 price objective (down previously from $8.00) on shares of NantHealth in a report on Monday, August 21st. Finally, BidaskClub upgraded NantHealth from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.30.
NantHealth (NYSE NH) opened at 3.74 on Wednesday. The stock’s 50 day moving average price is $4.27 and its 200 day moving average price is $4.27. NantHealth has a 1-year low of $3.67 and a 1-year high of $13.26. The firm’s market cap is $456.08 million.
NantHealth (NYSE:NH) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.32). The firm had revenue of $26.23 million during the quarter, compared to analyst estimates of $31.28 million. NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The company’s quarterly revenue was down 16.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.15) EPS. Equities research analysts predict that NantHealth will post ($0.70) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “NantHealth Inc (NH) Rating Lowered to Hold at Zacks Investment Research” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/27/nanthealth-inc-nh-rating-lowered-to-hold-at-zacks-investment-research.html.
In other news, COO Ronald Allen Louks sold 26,820 shares of the company’s stock in a transaction on Friday, October 6th. The stock was sold at an average price of $4.28, for a total value of $114,789.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Hedge funds and other institutional investors have recently made changes to their positions in the company. DekaBank Deutsche Girozentrale purchased a new stake in shares of NantHealth during the second quarter valued at $245,000. Highbridge Capital Management LLC purchased a new stake in shares of NantHealth during the first quarter valued at $998,000. National Planning Corp purchased a new stake in shares of NantHealth during the second quarter valued at $473,000. Bank of America Corp DE lifted its holdings in shares of NantHealth by 366.4% during the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock valued at $125,000 after purchasing an additional 19,694 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of NantHealth by 20.2% during the second quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock valued at $1,792,000 after purchasing an additional 71,087 shares during the last quarter.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.